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Abstract 
Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a therapeutic challenge because of the high 
recurrence rate. Surgical intervention should be considered in patients who fail to improve after medical treatment. 
We monitored recurrence and revision surgery over 12 years after endoscopic sinus surgery in CRSwNP patients.
Methods: In this prospective cohort study, 47 patients with CRSwNP, who underwent primary or revision extended 
endoscopic sinus surgery, were followed. Clinical symptoms and total nasal endoscopic polyp score were evaluated 
before, 6 years and 12 years after surgery.
Results: Twelve years after surgery, 38 out of 47 patients (80.9%) were available for examination. There still was a 
significantly better symptom score and total nasal endoscopic polyp score compared to before surgery (P < 0.001). 
Within the 12-year follow-up period, 30 out of 38 patients developed recurrent nasal polyps, of which 14 patients 
underwent additional revision surgery. Comorbid allergic sensitization and tissue IL-5 levels were found to be signifi-
cant predictors for the need of revision surgery.
Conclusions: This long-term cohort study, investigating the outcome after surgery in CRSwNP, showed that, despite 
the low number of patients, 78.9% of patients with CRSwNP were subject to recurrence of the disease and 36.8% to 
revision surgery over a 12-year period.
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Background
The treatment of chronic rhinosinusitis with nasal poly-
posis (CRSwNP) is a therapeutic challenge for ENT-spe-
cialists, pulmonologists, and allergists. This inflammatory 
disease of the nose and paranasal sinuses with nasal 
polyps (NP) accounts for substantial health care expen-
ditures in terms of oﬃce visits, antibiotic prescriptions, 
lost workdays and missed school days [1]. CRSwNP is 
frequently associated with asthma and intolerance for 
aspirin or non-steroidal anti-inflammatory drugs [called 
aspirin exacerbated respiratory disease (AERD)] [2]. 
This diﬃcult-to-treat group suﬀers from a more severe 
upper and lower airway disease, reflected by high NP 
recurrence and frequent need of endoscopic sinus sur-
gery (ESS) [3, 4]. The relationship between CRSwNP 
and allergy remains incompletely defined and there is no 
causal association proven [2].
Overall it has been stated that CRSwNP in Caucasians 
is an eosinophilic T helper (Th) 2 biased inflammation 
with high levels of local interleukin-5 (IL-5) and immu-
noglobulin E (IgE) [5]. Some progress has been made in 
elucidating the underlying pathomechanism of CRSwNP. 
For example, the role of Staphylococcus aureus as an 
important disease modifier has been demonstrated [6].
Due to the high recurrence rate, the goal of the treat-
ment of nasal polyps is to achieve and maintain clinical 
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control. In other words, patients should not have symp-
toms, or the symptoms should not be bothersome, if 
possible combined with a healthy or almost healthy 
mucosa and only local treatment [2]. The medical 
treatment in CRSwNP is based on topical or intrana-
sal corticosteroids, systemic or oral corticosteroid and 
antibiotics [2].
Over time, ESS evolved to be the treatment of choice 
in CRSwNP, when conservative treatment failed. When 
considering the eﬃcacy of surgery in CRSwNP, few rand-
omized controlled trials are available but the studies have 
demonstrated that sinus surgery in patients with nasal 
polyps can result in a prolonged reduction of nasal symp-
toms and an improvement of quality of life [7–11]. How-
ever, regardless of the surgical technique applied, a fair 
number of patients will present with recurrent CRSwNP 
disease at some point in time. Disease recurrence ranged 
from 4 to 60% in CRSwNP with a median of 20% across 
all studies reviewed over maximum 2 years [8, 12]. When 
NP recurrence occurs patients sometimes undergo revi-
sion surgery. The revision surgery rate varies between 4 
and 27% with follow-up periods varying between 12 and 
60 months [7, 12].
Diﬀerent studies have examined prognostic factors, like 
tissue eosinophilia, aﬀecting the success of endoscopic 
sinus surgery [13]. Surgery removes the disease burden 
but also increases the eﬃcacy of postoperative medi-
cal treatment. Prolonged postoperative medical treat-
ment with topical corticosteroid sprays would appear to 
improve outcomes after ESS in CRSwNP [2].
The impact of diﬀerent comorbidities has also exten-
sively been investigated. Studies contradict each other 
about the influence of allergic sensitization on the 
outcome of ESS [12]. However, diﬀerent studies have 
observed that CRSwNP patients with asthma or AERD 
have higher recurrence rates [4, 12, 14, 15].
Though, there are a lot of studies investigating the out-
comes after ESS, the follow-up is in most studies short 
(12 months) and retrospective. Some scarce studies per-
formed a longer follow–up between 5 and 20 years, but 
these studies use a wide variation of surgical techniques 
[4, 15, 16]. There is also a lack of knowledge of risk fac-
tors that might increase the likelihood of NP recurrence 
and revision surgery. Therefore, we performed a prospec-
tive cohort study in CRSwNP after ESS over a 12-year 
follow-up period. To minimize confounding factors, one 
surgeon performed a standardized surgical procedure in 
all patients. Further, at baseline all patients were exten-
sively characterised based on clinical characteristics, 
comorbidities and inflammatory factors in serum, nasal 
secretions and tissue. The goal of our study was to look 
at NP recurrence and the need of revision surgery over a 
12-year follow-up period after surgery.
Methods
Patients and study design
The patient population of this 12-year prospective cohort 
study covers 47 patients, 18 years or older, with CRSwNP 
diagnosed based on history, clinical examination, nasal 
endoscopy and CT scan, following the current EPOS 
guidelines [2]. All patients underwent extended ESS for 
nasal polyposis at the department of Otorhinolaryngol-
ogy of the Ghent University, Belgium, between 1998 and 
2000. The description of the surgical technique can be 
found in this article’s Additional file 1.
Before surgery, all patients underwent skin prick test-
ing for common aero-allergens to diagnose allergic sensi-
tization [17]. The presence of asthma was investigated by 
a lung physician [18] and the diagnosis of aspirin intoler-
ance was primarily based on the clinical picture, namely 
the presence of asthma, nausea, erythema or other com-
plaints shortly after ingestion of aspirin or NSAIDs. The 
exclusion criteria were pregnancy, cystic fibrosis, pri-
mary ciliary dysfunction, Kartagener syndrome, parasitic 
infection, and fungal infections.
In the scope of this study, three visits at the ENT-
department were organized: pre-operatively, approxi-
mately 6 and 12 years after initial surgery.
The ethics committee of Ghent University Hospital 
approved the study and all patients provided written 
informed consent before participation in the study.
Outcome measures
As primary outcome NP recurrence and the need of revi-
sion surgery were examined. The NP recurrence over 
12 years’ time was defined as a nasal polyp score greater 
than 0 at one of the two follow-up visits or a history of 
revision surgery for recurrent NP during the 12-year fol-
low-up period. The revision surgery rate is based on the 
exact surgical dates collected at each visit and by revision 
of medical records.
At each time point the following data were collected: 
demographics, comorbidities, symptom score (nasal 
obstruction, rhinorrhea, smell disturbance, sneezing, 
headache and eye symptoms), total nasal endoscopic 
polyp score (Davos score), history of previous surgery, 
medication use, general therapeutic response and EPOS 
control test. More detailed information can be found in 
this article’s Additional file 1.
Collection of tissue, serum and nasal secretion
Nasal polyp tissue, nasal secretion and serum were col-
lected and investigated for diﬀerent inflammatory mark-
ers [IL-5, IL-5Rα, TGF-β1, MPO, IL-18, ECP, total IgE 
and specific IgE antibodies against S. aureus enterotoxins 
(SAE-IgE)]. More detailed information about the used 
techniques can be found in this article’s Additional file 1.
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Statistics
Data are expressed as absolute numbers and percentages 
for categorical and as median and interquartile range 
(IQR) for continuous variables. Further details about sta-
tistics can be found in this article’s Additional file 1.
Results
Patient characteristics
Forty-seven CRSwNP patients were included prior to 
ESS. Table  1 shows the clinical baseline characteristics 
of these 47 patients. A follow-up was performed over 
12 years and in 2006 and 2012 patients were invited for 
an extensive follow up visit. After 12 years the response 
rate was 79% (38 out of 47), of which 19 patients under-
went in 2000 primary surgery and 19 underwent revi-
sion surgery. We show in Table  2 the clinical baseline 
characteristics of both groups and we observe at base-
line a significant higher amount of IL-5, IL-5Ra and 
ECP in patients undergoing revision surgery compared 
to primary surgery. Over the 12-year period 3 patients 
deceased, 4 patients could not be traced, and 2 patients 
were not prepared to participate. 
Nasal obstruction and smell disturbance improved 
12 years after surgery
Smell disturbance and nasal obstruction were the most 
predominant symptoms pre-operatively, as shown in 
Fig. 1. These symptoms are scored bothersome, i.e. mod-
erate to severe, in 91.9% and 89.2% patients respectively 
for smell disturbance and nasal obstruction. Twelve 
years after surgery the smell disturbances (P < 0.01) and 
the nasal obstruction (P < 0.001) were still significantly 
improved compared to baseline (see Fig. 1). Rhinorrhoea 
and headache, two other symptoms mentioned in the 
EPOS definition, were also pre-operatively reported as 
bothersome in 51.3% and 40.5% of the patients respec-
tively. After 12  years those complaints decreased to 
respectively 18.4% and 13.1%. Compared to the afore-
mentioned symptoms, patients were less troubled by 
sneezing and eye symptoms pre-operatively and during 
follow-up.
Nasal polyps are absent in 40% of the patients 12 years 
after surgery
In 2000, prior to ESS, all patients had considerable 
nasal polyps (Fig.  2). Compared to the NP score prior 
to ESS, the NP score was significantly decreased in 2006 
(P < 0.05) and in 2012 (P < 0.001). Twelve years after ESS, 
endoscopic examination of the nasal cavity showed in 
40% of the patients no nasal polyps. However, this per-
centage also includes patients that underwent revision 
surgery during the 12-year follow-up study. This percent-
age thus underestimates the presence on nasal polyps 
over the 12-year period.
78.9% of the patients ‘ever’ experienced recurrence 
of nasal polyps
Thirty out of 38 CRSwNP patients or 78.9% developed 
NP recurrence at a certain time point during 12 years of 
follow-up. Figure  3a shows the development of recur-
rence over time.
Comparing the ‘NP recurrence’ (N = 30) and 
‘no recurrence’ group (N = 8; see Additional file  1: 
Table S1), we identified that 60% of the NP recurrence 
Table 1 Baseline clinical characteristics in  the  group 
included in 2000 (N = 47)
N number, IQR interquartile range, BDL below detection level
Baseline clinical characteristics (N = 47)
Clinical characteristics
 Men/women, N/N (%/%) 33/14 (70.2/29.8)
 Age (y), median (IQR) 49 (37–58)
 Primary/revision ESS in 2000, N/N (%/%) 22/25 (46.8/53.2)
 Comorbidity
  Allergic sensitization, N (%) 24 (51.1)
  Asthma, N (%) 18 (38.3)
  AERD, N (%) 11 (23.4)
 Total NP score, median (IQR) 4 (3–6)
 Total symptom score, median (IQR) 8 (7–11)
Tissue biomarkers, median (IQR)
 IL-5 (pg/ml) 133.24 (43.00–338.58)
 Detectable IL-5, N (%) 31 (66.0%)
 IL-5Rα (pg/ml) 5003.01 (1765.61–21,069.23)
 TGF-β1 (pg/ml) 9534.22 (7457.03–20,760.85)
 MPO (ng/ml) 6878.56 (2805.72–14,874.40)
 IL-18 (pg/ml) 15,373.60 (6738.21–22,019.14)
 ECP (mg/l) 7.46 (1.84–14.87)
 Total IgE (kU/l) 432.30 (146.30–1155.90)
 IgE Grass mix 1 (kU/l) 3.88 (0.00–5.78)
 IgE Tree mix 9 (kU/l) 4.30 (0.00–8.03)
 IgE House dust mite mix 2 (kU/l) 4.08 (0.00–8.03)
 Detectable IgE to SAE, N (%) 18 (39.1)
Nasal secretion biomarkers, median (IQR)
 IL-5 (pg/ml) 30.00 (30.00–131.21)
 IL-5Ra (pg/ml) 1135.84 (497.57–5357.62)
 ECP (mg/l) 0.53 (0.25–1.16)
 IgE (kU/l) 283.44 (109.38–440.85)
Serum biomarkers, median (IQR)
 IL-5 (pg/ml) BDL
 IL-5Ra (pg/ml) 414.90 (297.00–744.70)
 ECP (µg/l) 26.10 (21.00–40.00)
 IgE (kU/l) 157.0 (48.5–278.0)
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group had comorbid allergic sensitization however 
not significant diﬀerent with 25% in the ‘no recur-
rence’ group (P = 0.117). Figure 4a shows the contribu-
tion of asthma and AERD. In the NP recurrence group 
80.0% expressed asthma and 90.0% AERD compared to 
78.3% asthma and 75.0% AERD in the non-recurrence 
group (Fig. 4a). The logistic regression showed a trend 
towards increased risk of NP recurrence in allergic 
patients (OR 4.5, 95% CI 0.78 to 26.1, P = 0.094) how-
ever not significant. For asthmatic patients (OR 1.1, 
95% CI 0.22 to 5.5, P = 0.898) and patients with AERD 
(OR 3.0, 95% CI 0.32 to 28, P = 0.336) the risk is less 
obvious. This is confirmed by the Kaplan–Meier graphs 
(allergy Fig.  3b P = 0.093; asthma Fig.  3c P = 0.738; 
AERD Fig. 3d P = 0.136).
Looking at the tissue markers there was no statistical 
diﬀerence between tissue IL-5, ECP and IgE (see Table S1 
in Additional file 1).
The non-significant influence of tissue IL-5 (Fig.  3f; 
P = 0.233), IgE (Fig. 3g; P = 0.446) and SAE-IgE (Fig. 3h; 
P = 0.459) on the development of NP recurrence over 
time is shown in the Kaplan–Meier figures.
36.8% of the patients underwent revision surgery
Fourteen out of 38 or 36.8% of the CRSwNP patients 
had a need of revision surgery in the 12-year follow-
up period. Consequently over 12-year follow-up the 
Table 2 Baseline clinical characteristics in patients, who were followed for 12 year (N = 38), with primary or revision ESS 
at baseline
Italic values indicate significance of P value (P < 0.05)
N number, IQR interquartile range, BDL below detection level, ND not done
Primary ESS Revision ESS P value
N = 19 N = 19
Baseline clinical characteristics (N = 38)
Clinical characteristics
 Men/women, N/N (%/%) 13/6 (68/32) 12/7 (63/37) 1.00
 Age (y), median (IQR) 44 (31–54) 47 (37–53) 0.863
 Comorbidity
  Allergic sensitizaion, N (%) 10 (53) 10 (53) 1.00
  Asthma, N (%) 5 (26) 10 (53) 0.184
  AERD, N (%) 3 (16) 7 (37) 0.269
 Total NP score, median (IQR) 4 (3–5) 4 (4–6) 0.644
 Total symptom score, median (IQR) 8 (7–12) 9 (8–12) 0.443
Tissue biomarkers, median (IQR)
 IL-5 (pg/ml) 86.02 (43.00–237.87) 228.14 (133.24–484.44) < 0.05
 Detectable IL-5, N (%) 10 (53) 16 (84) 0.079
 IL-5Rα (pg/ml) 2704.74 (1116.04–13,162.88) 15,383.50 (4036.26–28,350.59) < 0.05
 TGF-β1 (pg/ml) 8934.18 (7356.03–15,825.42) 12,769.26 (7562.52–27,256.90) 0.477
 MPO (ng/ml) 5251.91 (2634.00–11,020.06) 9255.17 (4602.93–19,868.30) 0.061
 IL-18 (pg/ml) 14,982.30 (7761.63–25,611.80) 15,051.30 (4698.93–19,633.68) 0.354
 ECP (mg/l) 5.71 (0.86–12.93) 13.48 (4.75–28.46) < 0.05
 Total IgE (kU/l) 322.95 (146.30–1348.16) 432.30 (251.83–1156.39) 0.639
 Detectable IgE to SAE, N (%) 8 (42) 8 (42) 1.00
Nasal secretion biomarkers, median (IQR)
 IL-5 (pg/ml) 30.00 (30.00–109.22) 94.81 (30.00–169.86) 0.285
 IL-5Rα (pg/ml) 667.55 (439.40–791.74) 2897.67 (562.93–10,030.07) 0.076
 ECP (mg/l) 0.36 (0.12–0.79) 0.54 (0.32–3.57) 0.100
 IgE (kU/l) 174.15 (40.49–312.94) 324.35 (100.14–662.78) 0.394
Serum biomarkers, median (IQR)
 IL-5 (pg/ml) BDL BDL ND
 IL-5Ra (pg/ml) 334.60 (235.60–710.05) 414.90 (364.30–866.60) 0.471
 ECP (µg/l) 26.10 (21.60–45.15) 23.90 (19.75–189.50) 0.601
 IgE (kU/l) 217.00 (51.15–715.00) 50.20 (29.35–189.50) 0.110
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patient group can be divided in three groups: no recur-
rence (21.05%), NP recurrence but no revision ESS 
(42.11%) and NP recurrence with revision ESS (36.84%).
Figure  5a illustrates Kaplan–Meier survival analysis 
for revision surgery within the 12-year follow-up based 
on the date of revision surgery, with an overall ‘surgery-
free rate’ of 84.2% (32/38) at 6 years and 63.2% (24/38) 
at 12-year follow-up. The time to revision ESS ranged 
from 18 to 153 months, with a median of 91 months.
The possible contribution of allergic sensitization, 
asthma and AERD to the risk of revision surgery was 
investigated and only allergic sensitization could be 
identified as a significant predictor for the need of revi-
sion surgery during follow-up (OR 6.1, 95% CI 1.3 to 
28, P < 0.05 in allergic sensitization). The percentage 
patients who underwent revision surgery in asthmat-
ics (53.3%) and patients with AERD (60.0%) was higher 
compared to patients without asthma (30.4%) or AERD 
(28.6%), however there was no statistical diﬀerence of 
revision surgery in the presence or absence of asthma 
and AERD (Fig. 4b).
Fig. 1 Symptoms, expressed as no, mild, moderate or severe are shown as the percentage of study population that experience complaints with the 
respective severity, at each time point (2000 N = 47, 2006 N = 27 and 2012 N = 24). The percentages are marked in the bars. **P < 0.01; ***P < 0.001
Fig. 2 The total nasal endoscopic polyp score expressed as Davos 
score between 0 and 6. The total nasal endoscopic polyp score is 
divided in four groups and the percentage of study objects with a 
certain Davos score are shown at the three time points (2000 N = 47, 
2006 N = 27 and 2012 N = 24). *P < 0.05; ***P < 0.001
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Moreover, the survival curve showed that the ‘surgery-
free survival rate’ was significantly longer in non-allergic 
patients compared to allergic patients (Fig. 5b; P < 0.05). 
The ‘surgery-free survival rate’ for revision ESS did not 
significantly diﬀer in patients with primary or revision 
surgery (Fig.  5e; P = 0.220), in patients with or without 
asthma (Fig. 5c; P = 0.350) and in patients with and with-
out AERD (Fig. 5d; P = 0.098).
Comparing the baseline characteristics, tissue IL-5 
is significantly higher in patients undergoing revision 
surgery [360.84  pg/ml (103.92–521.84)] compared to 
patients who did not need revision surgery (with and 
without NP recurrence; 112.94  pg/ml (43.00–228.88); 
P < 0.05; see Additional file 1: Table S2). Importantly, we 
identified tissue IL-5 as a significant predictor for revi-
sion surgery over the follow-up period (OR 1.004, 95% CI 
1.001 to 1.008, P < 0.05). This implicates that the higher 
the IL-5 levels pre-operatively the higher the risk for a 
revision surgery.
Additionally, tissue IgE (Fig. 5g; P = 0.166) or SAE-IgE 
(Fig. 5h; P = 0.294) was not a predictive factor for revi-
sion surgery.
Medication use is an important cornerstone of treatment
The use of medication did not significantly diﬀer between 
the 3 moments of contact, although asthma medication 
use tended to be higher during follow-up (Additional 
file  1: Fig.  S1). In 2006 64.0% of patients and in 2012 
52.6% of patients used intranasal corticosteroids as an 
ongoing treatment, compared to 57.9% pre-operatively. 
Additionally, 5 patients received during the 12-year fol-
low-up period monoclonal antibodies in double blind 
randomized controlled trials (3 patients received anti-
IL-5 [22], 1 patient anti-IgE [25] and 1 patient both). 
Four of these patients demonstrated a clinical  response 
to the treatment, and four patients required surgery after 
termination of treatment. The Kaplan–Meier curves 
were generated for revision surgery and revision surgery 
plus biologics but did not show any diﬀerence.
General therapeutic relief after ESS is good
When inquiring general therapeutic relief after the ESS 
in 2000 over the 12-year period, 8 out of the 38 (21.1%) 
patients reported a complete, 36.8% a marked, 26.3% a 
moderate and 13.2% a slight relief over time.
The EPOS control test was performed retrospectively 
and showed that initially all patients (97.4%) were uncon-
trolled before surgery. Six years after surgery 40% was 
uncontrolled and 44% was partially controlled based on 
symptoms and medication needed. Only 16% was con-
trolled 6  years after surgery. At the endpoint, 12  years 
after inclusion, 47.4% was uncontrolled, 26.30% was par-
tially controlled and 26.30% was controlled.
We asked patients if they would do the ESS again 
12 years ago with the knowledge they have today. Thirty-
six (94.7%) out of the 38 patients answered ‘Yes’. Two 
patients (5.3%) answered ‘No’, of which one was due to 
postoperative bleeding.
Discussion
CRSwNP is a recalcitrant condition, which needs ongo-
ing treatment. This long-term prospective study inves-
tigated the outcome after ESS in patients suﬀering from 
CRSwNP over a 12-year period. We showed that 78.9% of 
the patients with CRSwNP were subject to recurrence of 
the disease and 36.8% to revision surgery over a 12-year 
period. This study diﬀered from previous follow-up stud-
ies by extensive characterization of the patients based on 
clinical characteristics and on local inflammatory param-
eters, like IL-5, IgE, SAE-IgE. This gave the opportunity 
to identify comorbid allergic sensitization and local IL-5 
as predictive risk factors for the need of revision surgery.
The presence of nasal polyps induces nasal obstruction 
and smell disturbance, which are considered the most 
abundant symptoms [2]. This study showed that 12 years 
after ESS a clinical significant improvement is observed 
based on subjective symptoms and objective nasal endo-
scopic polyp score. Thus, ESS may contribute to the long-
term alleviation of the subjective and objective burden of 
CRSwNP, which is in line with the findings in short term 
[8, 10, 16]. It is important to notice that our results were 
influenced by revision surgery, which was performed in 
certain patients over the 12-year follow up period and 
also by long-term post-operative medical treatment, like 
nasal corticosteroids.
Our results showed that a substantial part of the 
patients (78.9%) develop NP recurrence over time. In 
our study the NP recurrence rate after surgery was based 
on objective endoscopic visualization of polyps in the 
nasal cavity. The NP recurrence rates reported in previ-
ous research varied substantially for several reasons [4, 8, 
Fig. 3 The performance of NP recurrence expressed over time as a Kaplan–Meier curve (a). b The Kaplan–Meier curve in patients with or without 
allergic sensitization, c in patients with or without asthma, d in patients and with or without AERD and e in patients with primary or revision surgery. 
The Kaplan–Meier curves for NP recurrence rate based on the detection of IL-5 (f), presence of IgE higher than 100 kU/l (g) and detection of SAE IgE 
(h) in tissue
(See figure on next page.)
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19], including the short term duration of follow-up, dif-
ferent post-operative medical treatments, variations in 
the surgical techniques and diﬀerent definitions of NP 
recurrence (endoscopy, imaging, symptoms, etc.). Our 
study was unique due to the prospective and long-term 
approach. In this study, one surgeon performed a stand-
ardized surgical procedure at the university hospital of 
Ghent; thereby the influence of experience and technique 
was minimized [8, 20, 21].
Patients included in this study are extensively charac-
tarised by comorbid allergic sensitzation, asthma, aspirin 
hypersensitivity, IL-5 and ECP amounts in tissue. Unfor-
tunately, due to the limited number of patients of this 
study, we could not identify significant risk factors for NP 
recurrence.
Our data indicated that revision surgery was needed in 
36.8% of the CRSwNP patients over the 12-year follow-
up. The majority of studies investigating revision surgery 
Fig. 4 The percentage of NP recurrence, divided by the presence or absence of allergic sensitization, asthma and AERD are shown in a. Panel b 
shows the percentage of patients with revision surgery, divided for the presence or absence of allergic sensitzation, asthma and AERD. *P < 0.05
Fig. 5 The performance of revision surgery expressed over time as a Kaplan–Meier curve (a). b The Kaplan–Meier curve for revision surgery rates in 
patients with or without allergic sensitization, c in patients with or without asthma, d in patients and with or without AERD and e in patients with 
primary or revision surgery. The Kaplan–Meier curves for revision surgery rate based on the detection of IL-5 (f), presence of IgE higher than 100 kU/l 
(g) and detection of SAE IgE (h) in tissue
(See figure on next page.)
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have expressed relapse rates as a point estimate during a 
mean duration of follow-up [7, 12]. Kaplan- Meier sur-
vival analysis enables estimation of revision surgery rates 
across time and therefore our median time to revision 
ESS was 91 months or almost 8 years. Our study identi-
fied diﬀerent significant risk factors for the need of revi-
sion surgery like comorbid allergic sensitization; namely 
allergic patients underwent a revision surgery sooner 
than non-allergic patients. This strengthens the impor-
tance of allergic sensitization diagnosed pre-operatively 
by skin prick test as a possible predictive factor for a poor 
outcome. In literature, asthma and AERD could be with-
held as determinants for revision surgery [14, 15].
The pathophysiology of CRSwNP is characterized by 
high local IL-5 and IgE levels [5]. In the current study, 
tissue IL-5 levels were identified as a positive predic-
tive factor for the need of revision ESS. Patients with 
detectable IL-5 in tissue have an increased risk for the 
need of revision surgery over time. Our study proved 
that this cytokine, important in the pathophysiology of 
CRSwNP, also plays a pivotal role in the prognosis after 
ESS in CRSwNP patients. Currently, there is a therapeu-
tic option available, namely, Mepolizumab or anti-IL-5, 
which has been proven eﬀective in CRSwNP [22]. Per-
haps in the future this treatment can be proposed to pre-
vent NP recurrence and the need of revision surgery.
Local polyclonal tissue IgE is also a cardinal feature of 
the local inflammation present in CRSwNP [6]. Recent 
evidence has accumulated, suggesting that S. aureus 
enterotoxins induce a local polyclonal IgE formation 
combined with an increased risk for developing asthma 
[23, 24]. Local IgE are is higher revision surgery. Cur-
rently a targeted treatment against IgE, Omalizumab 
(anti-IgE), has proven favourable eﬀects in CRSwNP [25]. 
IgE can therefore be used as a prognostic and therapeutic 
factor in CRSwNP.
An important remark should be made, the clinical and 
inflammatory profile of the patients at baseline diﬀered. 
We believe that this could interfere with the results. 
We need to acknowledge that at baseline patients who 
already had surgery before 2000 were included. This 
group of revision surgery at baseline is believed to have 
a more severe local eosinophilic inflammation with high 
IL-5 and ECP.
In the future a similar study with a greater number of 
patients should be performed to confirm our results. The 
number of patients in this study is limited but this study 
shows the extent of recurrence and revision surgery in 
CRSwNP.
The study might be biased by the post-operative 
treatment. Generally, our patients were treated follow-
ing the EPOS guidelines, i.e. rinsing with physiologic 
water, nasal corticoids in spray and drops, occasionally 
doses of doxycycline or oral corticosteroids. Addition-
ally, 5 patients received during the 12-year follow-up 
period monoclonal antibodies in double blind rand-
omized controlled trials (3 patients received anti-IL-5 
[22], 1 patient anti-IgE [25] and 1 patient both). The 
clinical response of 4 patients emphasises the impor-
tance of new monoclonal treatment options next to 
surgery [26].
Finally, our study proved that the vast majority of 
the patients experienced ESS as a beneficial procedure 
that improved their general wellbeing. In some patients 
NP recurrence was diagnosed by nasal endoscopy dur-
ing the 12-year follow-up period, but they did not (yet) 
decide to perform a revision surgery, for example based 
on minimal symptoms, on attempts of conservative 
management or on time required to schedule a sur-
gery. This strengthens the importance of other subjec-
tive factors in the decision for revision surgery. This is 
in contrast to NP recurrence, which is an inflammatory 
pathophysiological mechanism, independent of subjec-
tive patient-related factors.
As conclusion, CRSwNP is a chronic condition with a 
high recurrence and revision surgery rate over 12 years 
follow-up. Sinus surgery for CRSwNP patients should 
not be the only treatment option but rather be a modal-
ity used to manage patients to remove the disease bur-
den and increase the eﬃcacy of post-operative medical 
therapy. Regular follow-up is important for this chronic 
disease and chronic treatment with topical corticoster-
oids should be emphasized. On the other hand, there 
is a need for new innovative treatments, which can 
postpone NP recurrence and the need of revision sur-
gery, like Omalizumab (anti-IgE) and Mepolizumab 
(anti-IL-5).
Our findings emphasize the role of a thorough pre-
operatively diagnostic evaluation and a targeted long-
term medical therapy additional to surgery. Patients 
should pre-operatively be informed about the marked 
likelihood of NP recurrence and the need of revision 
surgery.
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